Literature DB >> 18786587

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

Ana Paula Fernandes1, Míriam Maria Silva Costa, Eduardo Antônio Ferraz Coelho, Marilene Suzan Marques Michalick, Eloísa de Freitas, Maria Norma Melo, Wagner Luiz Tafuri, Daniela de Melo Resende, Vinícius Hermont, Christiane de Freitas Abrantes, Ricardo Tostes Gazzinelli.   

Abstract

In this study, we investigated in dogs the immunogenicity and protective immunity against Leishmania (Leishmania) chagasi infection induced by vaccination with a formulation containing the recombinant A2 protein, an amastigote specific antigen, and saponin. Vaccinated animals produced significantly increased levels of total IgG and IgG2, but not IgG1 anti-A2 antibodies, and remained negative in conventional leishmaniasis serodiagnostic methods. Significantly increased IFN-gamma and low IL-10 levels were detected in vaccinated animals before and after challenge, as compared to control animals. Importantly, while the symptoms onset appeared as early as three months after infection in most control dogs, 14 months after challenge, 5 out of 7 vaccinated dogs remained asymptomatic. Therefore, immunization with rA2 antigen was immunogenic and induced partial protection in dogs, and allowed the serological differentiation between vaccinated and infected animals, an important requirement for a canine visceral leishmaniasis (CVL) vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18786587     DOI: 10.1016/j.vaccine.2008.05.095

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  66 in total

1.  KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis.

Authors:  Yasuyuki Goto; Ajay Bhatia; Vanitha S Raman; Hong Liang; Raodoh Mohamath; Alessandro F Picone; Silvia E Z Vidal; Thomas S Vedvick; Randall F Howard; Steven G Reed
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.

Authors:  S S Kashino; C Abeijon; L Qin; K A Kanunfre; F S Kubrusly; F O Silva; D L Costa; D Campos; C H N Costa; I Raw; A Campos-Neto
Journal:  Parasite Immunol       Date:  2012-07       Impact factor: 2.280

3.  Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs.

Authors:  Felicitat Todolí; Inmaculada Galindo; Silvia Gómez-Sebastián; Mariano Pérez-Filgueira; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

4.  Safety Analysis of Leishmania Vaccine Used in a Randomized Canine Vaccine/Immunotherapy Trial.

Authors:  Angela Toepp; Mandy Larson; Tara Grinnage-Pulley; Carolyne Bennett; Michael Anderson; Molly Parrish; Hailie Fowler; Geneva Wilson; Katherine Gibson-Corely; Radhika Gharpure; Caitlin Cotter; Christine Petersen
Journal:  Am J Trop Med Hyg       Date:  2018-03-01       Impact factor: 2.345

Review 5.  The development and clinical evaluation of second-generation leishmaniasis vaccines.

Authors:  Malcolm S Duthie; Vanitha S Raman; Franco M Piazza; Steven G Reed
Journal:  Vaccine       Date:  2011-11-12       Impact factor: 3.641

6.  Molecular Analysis of A2-genes Encoding Stage-specific S Antigen-like Proteins among Isolates from Iranian Cutaneous and Visceral Leishmaniasis.

Authors:  Mahin Farahmand; Hasti Atashi Shirazi; Hossein Nahrevanian; Homa Hajjaran
Journal:  Iran J Basic Med Sci       Date:  2011-09       Impact factor: 2.699

7.  Evaluation of a prototype flow cytometry test for serodiagnosis of canine visceral leishmaniasis.

Authors:  Henrique Gama Ker; Wendel Coura-Vital; Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Nádia das Dores Moreira; Cláudia Martins Carneiro; Evandro Marques de Menezes Machado; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodolfo Cordeiro Giunchetti; Márcio Sobreira Silva Araújo; Eduardo Antonio Ferraz Coelho; Denise da Silveira-Lemos; Alexandre Barbosa Reis
Journal:  Clin Vaccine Immunol       Date:  2013-10-09

8.  Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts.

Authors:  Eduardo A F Coelho; Laura Ramírez; Mariana A F Costa; Vinicio T S Coelho; Vivian T Martins; Miguel A Chávez-Fumagalli; Dulcilene M Oliveira; Carlos A P Tavares; Pedro Bonay; Carlos Gómez Nieto; Daniel R Abánades; Carlos Alonso; Manuel Soto
Journal:  Clin Vaccine Immunol       Date:  2009-10-07

9.  Immunogenicity in dogs and protection against visceral leishmaniasis induced by a 14kDa Leishmania infantum recombinant polypeptide.

Authors:  Claudia Abeijon; Nada Daifalla; Greice Krautz-Peterson; Stefano Pizzirani; Gillian Beamer; Neuza M Frazatti-Gallina; Isaias Raw; Antonio Campos-Neto
Journal:  Trials Vaccinol       Date:  2016

Review 10.  Control of visceral leishmaniasis in latin america-a systematic review.

Authors:  Gustavo A S Romero; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2010-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.